Navigation Links
Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
Date:11/20/2009

ately be applied to other commercial vaccine products."

"Our progress with RiVax(TM) has been notable, and this grant award further validates the previous work and merits of our biodefense program," stated Christopher J. Schaber, PhD, President and CEO of Soligenix. "We look forward to working with our outstanding partners in this consortium to develop thermally stable biodefense vaccines to address two high-priority biothreats."

About RiVax(TM)

RiVax(TM) is Soligenix's proprietary vaccine developed to protect against exposure to ricin toxin and is the most advanced vaccine in the company's portfolio. RiVax(TM) induces a protective immune response in animal models of ricin exposure and is currently being evaluated in humans. One human Phase 1 clinical trial has been completed and a second trial is currently being conducted.

Results of the first Phase 1 clinical trial of RiVax(TM) established that the immunogen was safe and induced antibodies anticipated to protect humans from ricin exposure. The outcome of the study was published in the Proceedings of the National Academy of Sciences (Vitetta et al., 2006, PNAS, 105:2268-2273). The second trial, sponsored by UTSW, is currently evaluating a more potent formulation of RiVax(TM). Soligenix has developed processes for large-scale manufacturing and is further establishing correlates of the human immune response in non-human primates.

The development of RiVax(TM) has been sponsored through a series of overlapping challenge grants (UC1) and cooperative grants (U01) from the NIH, granted to Soligenix and to the University of Texas Southwestern Medical Center (UTSW) where the vaccine originated. The second clinical trial is being supported by a grant to UTSW from the US Food and Drug Administration's Office of Orphan Products Development. Soligenix and UTSW have collectively received approximately $25 million in grant funding from the NIH for RiVax(TM).
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Rules-Based Medicine Forms Biomarker Alliance With Covance Inc.
2. CareFusion Launches Knowledge Portal to Provide Actionable Information Across Product Platforms
3. Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the Donut Hole
4. Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
5. American University of Beirut Medical Team Successfully Performs First Artificial Heart Implant in Lebanon
6. DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
7. The Villa Group Informs on Mexico Travel Plans in Wake of Swine Flu Outbreak
8. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
9. Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF
10. Huntington Hospital Surgeon Performs First Single Port Resection on Colorectal Cancer Patient in CA
11. Raptor Pharmaceuticals Provides Update on Targeting Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Latanoprost Market, ... Developed by Pharmacia & Upjohn in 1995, latanoprost ... reduces intraocular pressure. As the first pressure- lowering ... name of Xalatan) entered China ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015  Perrigo Company ... that it has completed the acquisition of leading OTC ... at €200 million. The transaction is a clear demonstration ... the Company,s leading European distribution network spanning 36 countries.  ... Joseph C. Papa commented, "We are excited to ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de 2015 ... anunció hoy su participación en el  Congreso de ... soluciones cardiológicas más recientes y novedosas, entre ellas ... conectan a las personas y la tecnología con ... a diagnosticar, guiar los tratamientos y permitir atención ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions ... it should begin with the employer and employees getting together for meaningful group ...
(Date:8/28/2015)... ... ... Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back pain and associated ... pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received his Bachelor of ... earn his title of Doctor of Chiropractic from the Palmer College of Chiropractic and ...
(Date:8/28/2015)... ... ... Mendon, IL, home of the Adams County Fairgrounds, was treated once again to ... In its second year, the “Music With A Mission” benefit concert was held there ... “Music With A Mission” is to raise money to help fund music education programs ...
(Date:8/28/2015)... , ... August 28, 2015 , ... The newest therapy ... be available for general use any time soon, according to educational website Surviving Mesothelioma. ... therapy that received orphan drug designation for mesothelioma last week from the FDA, will ...
(Date:8/28/2015)... ... August 28, 2015 , ... External Counterpulsation, also known as ... is now selling External Counterpulsation (EECP or ECP) machines with a full clinic licence ... been in business since 2007 helping people prevent and reverse heart disease ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2
... associated with age, might affect women with diabetes or ... recent study .// ,The study shows elderly ... and are at an increased risk for developing cognitive ... women with pre-diabetes or diabetes was increased nearly two-fold. ...
... say that they have now found out that long-term use ... of cancer.// ,The trial results of the longest follow-up ... show cardiovascular death was reduced by 17 percent and coronary ... drug simvastatin, also known as Zocor, for 10 years compared ...
... 600 babies in the United States is born with an isolated ... cleft only // and no other birth defects. ,Researchers say ... if a couple will have a child born with a cleft ... According to researchers isolated clefts happen during early fetal development. ...
... a degenerative joint disease and one of the oldest ... the joint’s cartilage breaks down and the bones rub ... ,An international, multi-center study shows an effective treatment ... as Prexige. The drug was found to reduces gastric ...
... public places can improve the overall likelihood someone will ... AEDs -- devices capable of shocking the heart back ... 1,000 shopping malls, apartment complexes, and other public places ... volunteers in these communities were then trained in either ...
... recent study researchers say cancer patients who receive treatment have ... new study shows many doctors are not taking the necessary ... more than 100 oncologists to determine if the doctors were ... preventative measures used by the physicians. About 40 percent of ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: